Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

Next Previous
X
Search
Trial Profile

A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brazikumab (Primary) ; Brazikumab (Primary) ; Vedolizumab
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms EXPEDITION
  • Sponsors AbbVie; Allergan; AstraZeneca

    • Most Recent Events

    • 03 Jul 2023 Planned End Date changed from 21 Jan 2025 to 13 Oct 2023.
    • 03 Jul 2023 Planned primary completion date changed from 14 Nov 2023 to 13 Oct 2023.
    • 01 Jun 2023 Status changed from recruiting to discontinued, according to a AstraZeneca media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top